InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4C - quarterly 31 Jul 2014 12:19PM $0.255 $0.049 fallen by 80.78%
- Prana Alzheimers disease Development Program update 17 Jul 2014 4:02PM $0.250 $0.049 fallen by 80.40%
- Response to ASX Price Query 28 May 2014 3:11PM $0.220 $0.049 fallen by 77.73%
- Appendix 4C - quarterly 24 Apr 2014 5:58PM $0.210 $0.049 fallen by 76.67%
- Prana announces preliminary results of Alzheimer's Trial 31 Mar 2014 8:55PM $1.040 $0.049 fallen by 95.29%
- Trading Halt 31 Mar 2014 10:09AM $1.040 $0.049 fallen by 95.29%
- Appendix 4D Half Yearly Report and Accounts 26 Feb 2014 4:54PM $1.040 $0.049 fallen by 95.29%
- Prana Announces Successful Phase 2 Results in HD Trial 18 Feb 2014 5:03PM $0.915 $0.049 fallen by 94.64%
- Trading Halt 17 Feb 2014 9:05AM $0.915 $0.049 fallen by 94.64%
- Response to ASX Price Query 3 Feb 2014 10:19AM $1.305 $0.049 fallen by 96.25%
- Appendix 4C - quarterly 31 Jan 2014 5:19PM $1.250 $0.049 fallen by 96.08%
- Prana Provides Update on PBT2 AD Extension trial 11 Dec 2013 8:27AM $0.655 $0.049 fallen by 92.52%
- Prana completes PBT2 dosing in IMAGINE AD Trial 9 Dec 2013 10:25AM $0.625 $0.049 fallen by 92.16%
- Prana Provides Update on Clinical Trials for Alzheimers 18 Nov 2013 2:59PM $0.555 $0.049 fallen by 91.17%
- Prana's PBT2 Reverses Memory Loss in Normal Aging 31 Oct 2013 9:22AM $0.545 $0.049 fallen by 91.01%
- Appendix 4C - quarterly 24 Oct 2013 2:29PM $0.375 $0.049 fallen by 86.93%
- Prana Updates Progress on PBT2 Trials 13 Sep 2013 11:47AM $0.495 $0.049 fallen by 90.10%
- Parkinsons UK Awards GBP150,000 to Study Pranas PBT434 4 Sep 2013 9:44AM $0.640 $0.049 fallen by 92.34%
- Appendix 4E Preliminary Final Report and Statutory Accounts 30 Aug 2013 1:58PM $0.585 $0.049 fallen by 91.62%
- Response to ASX price query 26 Aug 2013 9:14AM $0.630 $0.049 fallen by 92.22%
- Appendix 4C - quarterly 31 Jul 2013 4:31PM $0.380 $0.049 fallen by 87.11%
- Prana Doses 1st Patient in PBT2 Alzheimers Extension Study 29 Jul 2013 9:47AM $0.355 $0.049 fallen by 86.20%
- Prana Completes Phase 2 Huntington Disease Trial with PBT2 23 Jul 2013 10:32AM $0.270 $0.049 fallen by 81.85%
- Prana receives approval for open label extension study in AD 3 Jul 2013 2:18PM $0.280 $0.049 fallen by 82.50%
- Pranas PBT434 shows potential as treatment in PD 20 Jun 2013 2:25PM $0.230 $0.049 fallen by 78.70%

151 - 175 of 331 results

Page 7 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.